Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $117.82

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given a consensus recommendation of “Moderate Buy” by the fourteen analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $117.8182.

Several equities analysts recently issued reports on DNTH shares. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 9th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday. Truist Financial boosted their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Robert W. Baird boosted their price target on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Finally, Wedbush boosted their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th.

Dianthus Therapeutics Trading Up 0.0%

Shares of NASDAQ DNTH opened at $76.45 on Friday. Dianthus Therapeutics has a twelve month low of $16.64 and a twelve month high of $96.50. The stock has a fifty day simple moving average of $87.15 and a 200-day simple moving average of $64.95. The stock has a market capitalization of $4.18 billion, a PE ratio of -18.51 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, equities analysts predict that Dianthus Therapeutics will post -3.82 earnings per share for the current year.

Insider Activity

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the transaction, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Ryan Savitz sold 114,367 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $83.00, for a total value of $9,492,461.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 149,121 shares of company stock worth $12,635,454 in the last 90 days. 3.02% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. increased its position in Dianthus Therapeutics by 0.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after purchasing an additional 139 shares during the period. First Horizon Corp purchased a new stake in shares of Dianthus Therapeutics during the 1st quarter worth approximately $32,000. Virtus Investment Advisers LLC boosted its stake in shares of Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after acquiring an additional 416 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.